î
îž
î
Neurosense Therapeutics Ltd
NRSNWîđ
āļāļđāđāļāļāļ āļđāļĄāļīāđāļāļĒāļĨāļ°āđāļāļĩāļĒāļ
0.292USD
0.000
āđāļ§āļĨāļēāļāļģāļāļēāļĢāļāļĨāļēāļÂ ïžETïžāļĢāļēāļāļēāļĨāđāļēāļāđāļē 15 āļāļēāļāļĩ
0.00āļĄāļđāļĨāļāđāļēāļāļĨāļēāļ
--P/E TTM
î
Intraday
1m
30m
1h
D
W
M
D
āļ§āļąāļāļāļĩāđ
0.00%
5 āļ§āļąāļ
+Infinity%
1 āđāļāļ·āļāļ
+Infinity%
6 āđāļāļ·āļāļ
+13.91%
āļāđāļāļāļĩāļāļāļāļķāļāļāļąāļāļāļļāļāļąāļ
-33.73%
1 āļāļĩ
+Infinity%
āļāļđāđāļāļāļ āļđāļĄāļīāđāļāļĒāļĨāļ°āđāļāļĩāļĒāļ
āļāļ°āđāļāļāļŦāļļāđāļ TradingKey
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨāļāļ°āđāļāļ
āļāđāļēāļ§āļŠāļēāļĢ
āļāļ°āļĄāļĩāļāđāļēāļ§āļŠāļēāļĢāđāļāļīāđāļĄāđāļāļīāļĄāđāļĢāđāļ§āđ āļāļĩāđ āđāļāļĢāļāļāļīāļāļāļēāļĄ...
āļāļąāļ§āļāļĩāđāļ§āļąāļāļāļēāļāļāļēāļĢāđāļāļīāļî
EPS
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
āļĢāļēāļĒāđāļāđāļĢāļ§āļĄ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
āļāđāļāļĄāļđāļĨ Neurosense Therapeutics Ltdî
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļNRSNW
āļāļĢāļīāļĐāļąāļNeurosense Therapeutics Ltd
āļāļĩāļāļĩāđāļMr. Alon Ben-Noon
āđāļ§āđāļāđāļāļāđhttps://www.neurosense-tx.com/
āļāļĢāļēāļŠāļēāļĢāļāļĩāđāđāļāļĩāđāļĒāļ§āļāđāļāļ
+1.30%
-1.28%
-0.76%
-7.93%
-0.50%
+0.32%
+0.18%
-3.27%
+3.61%
-3.32%
+2.36%
-2.53%
-0.80%
-0.15%
+1.08%
+8.74%
-3.00%
+0.12%
+0.12%
-2.74%āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāļāļāļāļīāļĒāļĄ
100513.61
-6113.94Â (-5.73%)
3239.19
-346.19Â (-9.66%)
3934.14
-76.00Â (-1.90%)
60.341
-0.542Â (-0.89%)
1.14755
-0.00435Â (-0.38%)
153.656
-0.535Â (-0.35%)
47.188
-1.019Â (-2.11%)
0.64839
-0.00543Â (-0.83%)
1.30136
-0.01252Â (-0.95%)
471.10
-33.60Â (-6.66%)
